Bellicum Pharmaceuticals Inc (BLCM)


Stock Price Forecast

June 30, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Bellicum Pharmaceuticals Inc chart...

About the Company

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

CEO

Richard Fair

Exchange

NASDAQ

Website

http://www.bellicum.com/

$31M

Total Revenue

13

Employees

$3M

Market Capitalization

-0.45

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BLCM News

Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today

7h ago, source: Zacks.com on MSN

In the latest market close, Biogen Inc. (BIIB) reached $219.40, with a +0.04% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.63%. Meanwhile, ...

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arcellx Inc (ACLX) and AdaptHealth (AHCO)

23h ago, source: Business Insider

and Rocket Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcellx Inc with a $79.70 average price target, representing a 15.9% upside. In a ...

Biocom 2024: Pharma looking for deals to be done

14d ago, source: BioWorld

“The M&A environment has kind of woken up a little bit,” Jay Stamatis, vice president and head of business development and acquisitions at Abbvie Inc., told the audience at Biocom California’s Global ...

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

19d ago, source: Hosted on MSN

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.99 per share a year ago. These ...

Allogene Therapeutics: Redefining LBCL Treatment with Innovative ALPHA3 Trial and Promising Cema-cel Therapy

3d ago, source: Business Insider

Begin your TipRanks Premium journey today. Allogene Therapeutics (ALLO) Company Description: Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...